

## Press Release

### Cellzome announces translational medicine award to use *Kinobeads*<sup>™</sup> to profile the expressed kinome in early inflammatory arthritis

**Cambridge, United Kingdom and Heidelberg, Germany, 2<sup>nd</sup> October 2008:** Cellzome (Cambridge, UK and Heidelberg, Germany) announces the award of a Medical Research Council Pilot Industry Collaboration grant with Professor Christopher Buckley and Dr Karim Raza in the Department of Rheumatology and Medical Research Council Centre for Immune Regulation, University of Birmingham Medical School UK, to profile the expressed kinome in early inflammatory arthritis.

This project brings together three novel elements: a unique cohort of well characterised patients with very early inflammatory arthritis, refined ultrasound guided joint aspiration and biopsy and a new technology called *Kinobeads*<sup>™</sup> that allow quantitative profiling of the expression levels and activation states of kinases isolated directly from patient cells.

David Simmons, Cellzome Chief Scientific Officer said: "This award will allow us to use our innovative approach to kinase drug discovery based on *Kinobeads*<sup>™</sup> to directly study the signatures of the expressed kinome in the very early stages of arthritis. We hope this will point to new targets for early therapeutic intervention. We are very pleased to have been awarded the grant with the Rheumatology Research Group in Birmingham who are leaders in the field of studying the mechanisms that drive early inflammatory disease."

Prof Buckley and Dr Raza commented: "We are delighted to be working with Cellzome as partners in this MRC Pilot scheme to gain new insights into the mechanisms that underlie early arthritis."

The Pilot Industry Collaboration Award scheme was established by the UK Medical Research Council and MRC Technology to encourage collaborative research between MRC-funded researchers and industry.

Earlier this year, Cellzome was already awarded a prestigious German grant in connection with the Integrated German Genome Network (NGFN). The grant provides funding for three years to study the Systems Biology of Genetic Diseases together with Prof. Hans Lehrach's department at the Max-Planck-Institute for Molecular Genetics.

#### For further information please contact:

##### Cellzome:

David Simmons, PhD, MBA  
Chief Scientific Officer  
Tel: +49 (0) 6221-137 57-100  
press@cellzome.com

##### Media Contact:

Hogarth Partnership  
Sarah MacLeod  
Tel: +44 (0) 207 357 9477

#### About Cellzome Inc.

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by *Kinobeads*<sup>™</sup>, a proprietary technology for studying simultaneously multiple kinases in their native state, in relevant cell types.

Cellzome is applying its distinctive *Kinobeads*<sup>™</sup> technology to the discovery and development of novel, selective, small-molecule kinase inhibitors targeting key inflammatory mediators such as PI3K $\gamma$  and  $\delta$ , Zap-70, Jak3 and mTOR, as potential oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and asthma. Cellzome has also identified potent and selective inhibitors of LRRK2, a target implicated in Parkinson's disease which has proved intractable in many standard screens.

In September 2008 Cellzome and GlaxoSmithKline announced a significant, worldwide, strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases, using Cellzome's *Kinobeads*<sup>™</sup> technology. In addition, Cellzome has a collaboration with Johnson & Johnson focused on the discovery of novel medicines for the treatment of Alzheimer's disease.

Cellzome's holding company is domiciled in the US and it employs about 90 people at its two operating subsidiaries in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: [www.cellzome.com](http://www.cellzome.com).